GnC News (1 April, 2020): Human trials for Coronavirus vaccine will begin imminently – but even if they go well and a cure is found, there are many barriers before global immunisation is feasible. (more…)
The day after the first clinical trial of a coronavirus vaccine candidate began in the U.S. on March 16, China announced the first clinical trial of its own coronavirus vaccine candidate, called Ad5-nCoV, jointly developed by Cansino Biologics Inc. and the Academy of Military Medical Sciences of China, based on Cansino’s adenovirus-based viral vector vaccine technology platform, which had been successfully used for developing Ebola virus disease vaccine back in 2017. Ad5-nCoV is a recombinant novel coronavirus vaccine, genetically engineered with the replication-defective adenovirus type 5 as a vector to express the spike protein of the novel coronavirus (SARS-CoV-2).
Novel COVID-19 vaccine and mAb development from spike protein structure: NIH is almost to control the breakthroughChief Editor
NIH Vaccine Research Center and University of Texas (UT) Austin team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. It provide complete insight for Novel COVID-19 vaccine and mAb development for the new coronavirus, published in Science Magazine on Wednesday (19 February 2020). (more…)
Dr. Muhammad Irfan-maqsood, founder of GnC has been awarded as young entrepreneur of 2018 by the deputy youth minister of Iran. (more…)
Genes&Cells as an international platform of researchers and research institutes in ECO and BSEC countries for Genes and Cells based therapies has been launched. (more…)